BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11548847)

  • 21. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation.
    Shimazaki C; Uchiyama H; Fujita N; Araki S; Sudo Y; Yamagata N; Ashihara E; Goto H; Inaba T; Haruyama H
    Exp Hematol; 1995 Dec; 23(14):1497-502. PubMed ID: 8542937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice.
    Misaki M; Ueyama Y; Tsukamoto G; Matsumura T
    Br J Cancer; 1998 Mar; 77(6):884-9. PubMed ID: 9528829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients.
    Meehan KR; Slack R; Gehan E; Herscowitz HB; Areman EM; Ebadi M; Cairo MS; Lippman ME
    J Hematother Stem Cell Res; 2002 Apr; 11(2):415-21. PubMed ID: 11983113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis.
    Körbling M; Giralt S; Khouri I; Mirza N; Donato M; Anderlini P; Fischer H; Andreeff M; McMannis J; Champlin R
    J Clin Apher; 2001; 16(2):82-7. PubMed ID: 11746533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
    Waller CF; von Lintig F; Daskalakis A; Musahl V; Lange W
    Bone Marrow Transplant; 1999 Jul; 24(1):19-24. PubMed ID: 10435729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
    Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
    Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor.
    Bensinger W; Singer J; Appelbaum F; Lilleby K; Longin K; Rowley S; Clarke E; Clift R; Hansen J; Shields T
    Blood; 1993 Jun; 81(11):3158-63. PubMed ID: 7684625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of lower CD34 yields after lowe dose G-CSF induction on long-term autologous stem cell transplantation outcome: A single center study.
    Vaezi M; Shakouri M; Souri M; Setaredan MA; Mossavi SA; Mohammadi S; Alimoghaddam K; Ghavamzadeh A
    Transfus Apher Sci; 2018 Apr; 57(2):265-271. PubMed ID: 29605509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
    Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD
    Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
    Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
    Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.
    Burns LJ; Weisdorf DJ; DeFor TE; Repka TL; Ogle KM; Hummer C; Miller JS
    Exp Hematol; 2000 Jan; 28(1):96-103. PubMed ID: 10658681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation.
    Larsson K; Björkstrand B; Ljungman P
    Support Care Cancer; 1998 Jul; 6(4):378-83. PubMed ID: 9695206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.
    Singh AD; Parmar S; Patel K; Shah S; Shore T; Gergis U; Mayer S; Phillips A; Hsu JM; Niesvizky R; Mark TM; Pearse R; Rossi A; van Besien K
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):288-293. PubMed ID: 29061534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
    Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.